Characterization of proteins, mRNAs, and miRNAs of circulating extracellular vesicles from prostate cancer patients compared to healthy subjects

• Published in: Frontiers in oncology Vol. 12; p. 895555
• Main Authors: Chisholm, Jolene, Haas-Neill, Sandor, Margetts, Peter, Al-Nedawi, Khalid
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 08.12.2022
• Subjects: circulating extracellular vesicles; extracellular vesicles; miRNA; mRNA; Oncology; proteomics; transcriptom; miRNA; transcriptom; mRNA; extracellular vesicles; proteomics; circulating extracellular vesicles
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.895555

Prostate cancer (PC) is the fifth leading cause of death in men globally. Measurement of the blood PSA level is still considered the gold-standard biomarker test for PC despite its high rate of delivering false positives and negatives that result in an inappropriate medical response, including overtreatment. We collected extracellular vesicles (EVs) from the blood plasma of PC patients with organ-confined, extracapsular-invading, and seminal vesicle–invading tumors and from healthy subjects. We examined the protein, mRNA, and miRNA content of these EVs using mass spectrometry (MS), a human PC PCR array, and a miScript miRNA PCR array, respectively. The proteomic analysis showed distinct groups of proteins that are differently expressed in each group of patients, as well as in healthy subjects. Samples from healthy subjects and each tumor type were used for both mRNA and miRNA arrays. The mRNA analysis showed distinct groups of mRNAs that were overexpressed in healthy or in one of the three tumor types but not in the EVs of the other groups. The miRNA analysis showed distinct groups of miRNAs as well. The fold of regulation in the expression of the identified mRNA and miRNA of each stage of the disease from healthy subjects showed that various mRNAs and miRNAs could discriminate the disease stage. Overall, our data suggest many molecular marker candidates for distinguishing between healthy subjects and PC patients using the cargo of circulating vesicles, as well as markers to discriminate between the different tumor types. Once verified, these markers might have a diagnostic value for PC.